The role of ixazomib as an augmented conditioning therapy in salvage autologous stem cell transplant (ASCT) and as a post-ASCT consolidation and maintenance strategy in patients with relapsed multiple myeloma (ACCoRd [UK-MRA Myeloma XII] trial): study protocol for a Phase III randomised controlled trial
This study will provide evidence to better define post-relapse treatment in MM.Trial registrationISRCTN,ISRCTN10038996. Registered on 15 December 2016.
Source: Trials - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Dexamethasone | Myeloma | Oral Cancer | Research | Stem Cell Therapy | Stem Cells | Study | Transplants